# GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

> **NCT05695508** · PHASE2 · RECRUITING · sponsor: **University of Heidelberg Medical Center** · enrollment: 160 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab (Tec)
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Talquetamab
- **DRUG:** JNJ-79635322

## Key facts

- **NCT ID:** NCT05695508
- **Lead sponsor:** University of Heidelberg Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2028-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05695508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05695508, "GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05695508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*